Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

In addition to the risk of cardiovascular events and neurological disorders, sympathomimetic decongestants have teratogenic potential, albeit weak, when taken during the first trimester of pregnancy, probably through disruption of the vascular system of the embryo and the pregnant woman. In the second and third trimesters of pregnancy, the fetus is exposed to the same adverse effects as the mother.


Sympathomimetic decongestants during pregnancy: risks for the unborn child. Prescrire international. 2016 Jun;25(172):153

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 27486644

View Full Text